This free sheet contains 100 accelerators and incubators you can apply to today, along with information about the industries they generally invest in.
This free sheet contains all the information about the top 100 unicorns, including their valuation, HQ's location, founded year, name of founders, funding amount and number of employees.
This free Notion document contains the best 100+ resources you need for building a successful startup, divided in 4 categories: Fundraising, People, Product, and Growth.
The biopharma sector is attracting major investment for developing new treatments. Shields Health Solutions, a specialty pharmacy accelerator, has raised $3.5 billion.
The field also includes companies like EGenesis, which is developing human compatible organs, and Cartography Biosciences, focused on cancer immunotherapies.
Below is our list of 100 Biopharma startups worth keeping an eye on.
Everything you need to raise funding for your startup, including 3,500+ investors, 7 tools, 18 templates and 3 learning resources.
Buy It For $97 $297 →Information about the industries, countries, and cities they generally invest in.
Get the Sheet for $50Information about their valuation, HQ's location, founded year, name of founders, funding amount and number of employees.
Get the Sheet for $50List of startup investors in the BioTech, Health, and Medicine industries, along with their Twitter, LinkedIn, and email addresses.
Get the Sheet for $50List of 250 startup investors in the AI and Machine Learning industries, along with their Twitter, LinkedIn, and email addresses.
Get the Sheet for $50List of 250 startup investors in the FinTech and Finance industries, along with their Twitter, LinkedIn, and email addresses.
Get the Sheet for $50Cartography Biosciences develops cancer immunotherapies by first mapping novel and highly specific tumor antigens. This proprietary approach allows them to create targeted treatments with the potential for greater efficacy against a patient's specific cancer.
Shields Health Solutions partners with hospitals to build and manage on-site specialty pharmacy programs. This model helps health systems provide integrated care for patients with complex, chronic conditions and generates new revenue.
NRG Therapeutics discovers and develops new medicines for neurodegenerative disorders like Parkinson's disease. Their work centers on creating therapeutic approaches that restore proper mitochondrial function.
Sparrow Pharmaceuticals develops targeted therapies for disorders related to corticosteroid excess. The clinical-stage biopharmaceutical company is advancing a lead product candidate to treat conditions such as Cushing's syndrome.
Salt AI builds a visual development platform for creating enterprise applications in the life sciences and health tech industries. Their contextual AI technology helps teams develop complex solutions without needing deep coding expertise.
EGenesis uses gene editing technology to develop human-compatible organs for transplantation. The company's work in genome engineering aims to address the global organ shortage and provide new treatments for end-stage organ failure.
Enlaza Therapeutics is pioneering the field of covalent biologics to create a new class of drugs for treating cancer. Their proprietary War-Lock™ platform engineers highly specific protein drugs with improved therapeutic properties.
AusperBio develops innovative drugs with the goal of curing chronic hepatitis B. Their work in biotechnology also extends to creating treatments for other major infectious diseases.
Retro Biosciences develops therapies to combat diseases driven by the aging process. The company's research pursues three distinct approaches, cellular reprogramming, autophagy, and plasma-inspired therapeutics, to achieve its mission of extending healthy human lifespan.
Opus Genetics develops gene therapies to treat rare inherited retinal diseases. Their work focuses on creating treatments for conditions that currently have limited or no options, potentially restoring vision for patients.
Our top 10 picks are just a small slice of the activity happening in the biopharma space. Altogether, these companies have raised billions of dollars to push science forward.
You'll find a mix of brand new ventures and more established names, with many using AI to discover new medicines. Here’s a look at the other startups shaping the industry.
| Startup | Main Industry | Year Founded | Amount Raised | Last Funding Round |
|---|---|---|---|---|
| Biotech | 2018 | $640.6M | Series D | |
| Biotech | 2021 | $187.3M | Series C | |
| Biotech | 2022 | £8.8M | Seed | |
| Biotech | 2011 | $8.7M | Series A | |
| Biotech | 2021 | $3B | Series A | |
| Biotech | 2020 | $2.5B | Grant | |
| Biotech | 2019 | $175.9M | Undisclosed | |
| Biotech | 2020 | $117M | Series C | |
| AI | 2014 | $114.9M | Venture Round | |
| Biotech | 2019 | $363M | Series C | |
| Manufacturing | 2016 | $79.4M | Series C | |
| Biotech | 2021 | $21.2M | Grant | |
| Biotech | 2011 | $131.1M | Grant | |
| Biotech | 2020 | $50M | Series B | |
| AI | 2023 | $5.5M | Seed | |
| Biotech | 2011 | $372.5M | Series D | |
| Biotech | 2017 | $79.7M | Venture Round | |
| AI | 2018 | $200M | Series B | |
| Biotech | 2025 | $205M | Series A | |
| Biotech | 2001 | $241.8M | Grant | |
| Biotech | 2010 | $37.6M | Venture Round | |
| Biotech | 2017 | $80.5M | Series B | |
| Biotech | 2017 | $52M | Series A | |
| Biotech | 2021 | $66.6M | Series A | |
| Biotech | 2018 | $30.1M | Venture Round | |
| Biotech | 2021 | $193M | Series B | |
| Biotech | 2023 | $300M | Series A | |
| AI | 2021 | $33.2M | Series A | |
| Biotech | 2018 | $220M | Series C | |
| Biotech | 2016 | $304.5M | Series C | |
| Biotech | 2006 | $480M | Private Equity | |
| Biotech | 2021 | CN¥500M | Series B | |
| Biotech | 2022 | $66.3M | Series A | |
| Biotech | 2003 | $102.3M | Grant | |
| Biotech | 2017 | $59.5M | Series A | |
| Biotech | 2018 | $16.1M | Series A | |
| Biotech | 2018 | $45.1M | Seed | |
| Biotech | 2020 | $173M | Series B | |
| Biotech | 2017 | £60M | Series B | |
| Biotech | 2017 | $166M | Series C | |
| Biotech | 2014 | $156.5M | Venture Round | |
| Biotech | 2021 | $160M | Seed | |
| Biotech | 2011 | CHF172M | Series C | |
| Biotech | 2016 | $295.2M | Series B | |
| Biotech | 2016 | $225M | Series A | |
| Biotech | 2020 | $86M | Venture Round | |
| Biotech | 2020 | $12M | Series A | |
| Biotech | 2017 | $278.5M | Series A | |
| AgTech | 2020 | $316.2k | Seed | |
| Biotech | 2016 | $38.4M | Grant | |
| Biotech | 2016 | $298.3M | Series C | |
| Biotech | 2009 | $44.5M | Series B | |
| Biotech | 2021 | CN¥199M | Series B | |
| Biotech | 2017 | SEK388M | Series A | |
| Biotech | 2014 | $102M | Venture Round | |
| Biotech | 2019 | $38.2M | Series C | |
| Biotech | 2011 | CN¥700M | Series B | |
| Biotech | 1919 | €1.5M | Grant | |
| Biotech | 2018 | $276M | Series C | |
| Biotech | 2018 | $121.1M | Debt Financing | |
| Biotech | 2015 | €193.1M | Grant | |
| Biotech | 2019 | €98.9M | Series A | |
| Biotech | 2015 | €39M | Series A | |
| Biotech | 2018 | $9.7M | Series A | |
| Biotech | 2024 | €63M | Series A | |
| Biotech | 2014 | €96.5M | Series C | |
| Biotech | 2020 | $77.9M | Grant | |
| Biotech | 2022 | €1.5M | Pre-Seed | |
| AI | 2020 | $391.7M | Series D | |
| Biotech | 2020 | $45.6M | Series B | |
| Biotech | 2018 | €7M | Seed | |
| Biotech | 1999 | €60M | Venture Round | |
| Security | 2011 | $282.1M | Series D | |
| Biotech | 2005 | €18M | Series D | |
| Biotech | 2013 | $332.4M | Series A | |
| Biotech | 2002 | CN¥1.6B | Series B | |
| Biotech | 2021 | $15M | Series A | |
| Biotech | 2020 | CN¥150M | Series B | |
| Biotech | 2015 | $230.9M | Series D | |
| Biotech | 2021 | CN¥177M | Series B | |
| Biotech | 2013 | CN¥500M | Series C | |
| Biotech | 2024 | €4.5M | Seed | |
| Biotech | 2008 | $98.9M | Series D | |
| Biotech | 2011 | £10.7M | Venture Round | |
| AI | 2015 | €34.2M | Venture Round | |
| Biotech | 2022 | $30M | Series A | |
| Biotech | 2018 | CN¥300M | Series C | |
| Biotech | 2021 | ₩22.8B | Series B | |
| Biotech | 2021 | $15M | Seed | |
| Biotech | 2019 | CN¥486.3M | Series B |
